PanCAN welcomes Jon Mahrt, Chief Executive Officer of Optum Rx and Chief Growth Officer of Optum to the Board of Directors.

The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

As part of our strategic approach to improve outcomes for pancreatic cancer patients, our Scientific and Medical Affairs team conducts independent and collaborative research. We disseminate important ...

American Cancer Society’s Cancer Facts & Figures 2023 reports that the five-year survival rate for pancreatic cancer has increased to 12%, progress that PanCAN’s initiatives helped to fuel.

About 20 percent of patients are eligible for surgery at diagnosis. Learn more about the types of surgery, such as the Whipple, and the importance of molecularly profiling the tumor tissue.

For the third year in the row, the pancreatic cancer five-year survival rate has increased one percentage point, to 13%, according to the American Cancer Society’s Cancer Facts & Figures 2024 Report.

For the first time in more than 10 years, the FDA has approved a new first-line treatment, called NALIRIFOX, for patients with metastatic pancreatic cancer.

Learn key information about the world’s toughest cancer, including its symptoms, to increase your chances of early detection and survival.

Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and ...

Learn about the common symptoms of the world’s toughest cancer, such as weight loss, digestive problems, back pain and more.

Itchy skin (with jaundice) can be a symptom of pancreatic cancer. Itching can also be a side effect of treatment. Get information on pancreatic cancer-related itching and ways to relieve it.